25-27 May 2027
Hamburg, Germany
25-27 May 2027
Hamburg, Germany
The right assay can accelerate discovery, improve decision-making, and reduce programme risk. Drawing on 45 years of combined industry experience across pharma, biotech, and CRO environments, this course provides a practical framework for designing and deploying assays that deliver robust, decision-enabling data.
The course examines best practices for assay optimisation, automation, standardisation, and fit-for-purpose evaluation, equipping scientists with the tools to develop high-quality assays, improve experimental rigour, and enable faster, more informed decisions throughout the drug discovery process. Participants will learn how to select and develop the most appropriate assay formats to address key biological questions, balancing relevance, robustness, scalability, throughput, and automation considerations. Through real-world case studies and practical examples covering both enzyme and cell-based assays, the course explores how assays are integrated into screening and characterisation cascades, how these cascades evolve during discovery programmes, and how assay strategies can provide earlier insights into mechanism and mode of action.
By the end of this course, participants will be able to:
Selecting and Optimising Assays
Building Effective Screening Cascades
Mechanistic and Mode-of-Action Understanding
Scalability, Throughput and Automation
Assay Quality and Fitness-for-Purpose
Denise Swift
Associate Director – HTS Group Lead, Sygnature Discovery
Denise Swift is a senior research leader with extensive experience in early-stage drug discovery and high-throughput screening (HTS). As Associate Director and HTS Group Lead, she oversees the strategic direction and operational delivery of screening campaigns, compound profiling, and early-stage research projects. Her work supports the identification of novel therapeutic targets and compounds, across therapeutic areas and target classes.
Alexandra Stowell
Senior Principal Scientist – Bioscience,?Sygnature Discovery
Alexandra Stowell is a senior researcher in Bioscience with more than 20 years’ experience across pharmaceutical, biotechnology and CRO environments, including over 17 years specialising in oncology drug discovery. She joined Sygnature in June 2021. She has led drug discovery programmes from hit finding through lead optimisation and preclinical development across multiple therapeutic areas. Her expertise spans enzymology assay development, compound profiling, hit finding and validation.?